<DOC>
	<DOCNO>NCT01987102</DOCNO>
	<brief_summary>An Open-Label , Multicenter , Phase I/II Clinical Trial Identify [ 6R ] 5,10-methylenetetrahydrofolate Dose Most Favorable Safety Prospect Confirmed Ability Mitigate High-Dose Methotrexate Induced Toxicity Treatment Osteosarcoma Patients</brief_summary>
	<brief_title>Investigation 6R 5,10-methylenetetrahydrofolate Rescue Therapy Osteosarcoma Patients Treated With HDMTX .</brief_title>
	<detailed_description />
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tetrahydrofolates</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Patients must histological evidence osteosarcoma include metastatic osteosarcoma .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Methotrexate</keyword>
	<keyword>rescue treatment</keyword>
</DOC>